A likely explanation is that the OR-gate CAR-T cells have slightly weaker reaction to CS1+ target cells compared to the single-input CS1 CAR-T cells, striking a balance that enables robust tumor killing without inducing premature functional exhaustion of the T cells. The gene discussed is SLAMF7; the disease is neoplasm.